MultiCell Technologies Relocates Corporate Headquarters

    -- the new address is: 68 Cumberland Street, Suite 301, Woonsocket,
       RI  02895.
    -- new phone number  is: (401) 762-0045
    -- the new fax number is:  (401) 762-0098

MultiCell Technologies, Inc. is a biopharmaceutical company developing new therapeutics including:

    MCT-125 for the treatment of primary fatigue in MS patients.
    MCT-175 for the treatment of relapsing-remitting MS.
    MCT-465 for the treatment of TLR3 positive breast cancers.
    MCT-475 for the treatment of TLR3 positive cervical cancers.

MultiCell also sells and/or licenses immortalized human liver cells to the pharmaceutical industry and holds patents on the Sybiol(R) synthetic bio-liver device and liver-derived adult human stem cells.

For more information about MultiCell Technologies, please visit http://www.multicelltech.com .

Caution Regarding Forward-Looking Statements

Any statements in this press release about MultiCell's expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and are forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). These statements are often, but not always, made through the use of words or phrases such as "believe," "will," "expect," "anticipate," "estimate," "intend," "plan," "forecast," "could," and "would." Examples of such forward looking statements include statements regarding the timing, design, scope, and anticipated results of our clinical development programs. MultiCell bases these forward- looking statements on current expectations about future events. They involve known and unknown risks, uncertainties and assumptions that may cause actual results, levels of activity, performance or achievements to differ materially from those expressed or implied by any forward-looking statement. For additional information about risks and uncertainties MultiCell faces, see documents MultiCell files with the SEC, including MultiCell's report on Form 10-KSB for the fiscal year ended November 30, 2007, and all our quarterly and other periodic SEC filings. MultiCell claims the protection of the safe harbor for forward-looking statements under the Act and each assume no obligation and expressly disclaim any duty to update any forward-looking statement to reflect events or circumstances after the date of this news release or to reflect the occurrence of subsequent events.

SOURCE MultiCell Technologies, Inc.

Copyright © 2009, PRNewswire
Copyright © 2009, NewsBlaze, Daily News

Tags: ,MTC,BIO,HEA,OTC,RI-MultiCellTech-move